arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Instil Bio, Inc.

TIL
$7.02 ▲ +0.06 (+0.86%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Instil Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $47.6M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -4.1% ↗
FCF / Share $-0.68 ↘
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-4.20M
↑ +85.1% —
FCF / Share Free cash flow per share
$-0.68
↓ -247.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
14
Financial Health ↑
26
Cash Quality ↓
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters